(RTTNews) - Geron Corp. (GERN) revealed the enrollment of the first patient in the company's clinical trial of human embryonic stem cell-derived oligodendrocyte progenitor cells, GRNOPC1. The primary objective of this Phase I study is to assess the safety and tolerability of GRNOPC1 in patients with "complete" American Spinal Injury Association Impairment Scale grade A thoracic spinal cord injuries.
The patient was enrolled at Shepherd Center, a 132-bed spinal cord and brain injury rehabilitation hospital and clinical research center in Atlanta.
Participants in the study must be newly injured and receive GRNOPC1 within 14 days of the injury.
Copyright(c) 2010 RTTNews.com, Inc. All Rights Reserved For comments and feedback: contact editorial@rttnews.com
上一篇：Most Americans Back Embryonic Stem Cell Research: Poll
下一篇：First Human Embryonic Stem Cell Lines Approved for Use Under New NIH Guidelines
Hepatology Hospital
China-Japan Union Hospital
The Second Hospital
Hospital Jilin Province
The Third Hospital
The First Hospital